ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BMY vs SNY // RETURN ON INVESTED CAPITAL (ROIC)

Bristol-Myers Squibb Company (NYSE) VS. Sanofi ADS (NASDAQ) • 15-METRIC TALLY: BMY 9 — SNY 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: BMY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. SNY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BMY SNY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 71.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE 13.30% 9.90% +3.40 BMY /roic <GO>
EV/EBITDA & P/E Valuation 16.3x 21.0x -4.70 BMY /valuation <GO>
Free Cash Flow Yield 10.24% 2.21% +8.03 BMY /fcf-yield <GO>
Operating Margin 17.90% 13.90% +4.00 BMY /operating-margins <GO>
Net Profit Margin 14.60% 10.90% +3.70 BMY /net-margins <GO>
Revenue Growth (YoY) -0.20% -1.10% +0.90 BMY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 4.02% 0.00% +4.02 BMY /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.24 3.74 -1.50 SNY /balance-sheet <GO>
Piotroski F-Score Quality 7/9 7/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.4 58.8 -8.40 SNY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.98 1.14 -0.16 SNY /macro-sensitivity <GO>
Forward P/E Multiple 16.6x 30.5x -13.90 BMY /forward-pe <GO>
Enterprise Scale & Market Cap $125.40B $105.19B $20.21B BMY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BMY REV SNY REV BMY GROSS % SNY GROSS % BMY FCF SNY FCF
FY 2025 $48.19B — 71.1% — $12.85B —
FY 2024 $48.30B — 71.1% — $13.94B —
FY 2023 $45.01B — — — $11.83B —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
SNY // BETA 1.14